

Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and Investment Services, Grifols, S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols informs that on December 11, 2025, the European Medicines Agency (EMA) has issued the Certificate of Compliance with Community legislation for the plasma supplied by Grifols Egypt for Plasma Derivatives (GEPD), the joint venture established in 2020 jointly between Grifols and Egypt's National Service Projects Organization.

This certification has been granted after the quality inspection to the plasma centers owned by GEPD and after the review by the EMA that all procedures, selection of donors, plasma obtention methods, quality controls, and storage (among others) comply with the quality and security standards required by European legislation.

This certification will allow not only to manufacture plasma products by GEPD but also to commercialize them throughout Europe and in all countries that follow EMA legislation.

The achievement of this certification from the EMA for the Egyptian plasma is a huge milestone for the Company and Grifols has been the first plasma company in accomplishing this significant step.

This recognition positions Egypt as the first country in Africa and the Middle East to operate a fully integrated plasma collection and processing system that meets the strictest international standards.

In Barcelona, on 16 December 2025

Núria Martín Barnés
Secretary to the Board of Directors